BPM31510

DRUG2 trials

Sponsors

BPGbio, AdventHealth Translational Research Institute

Conditions

GlioblastomaGlioblastoma MultiformeSarcopenia

Early Phase 1

Impact of Orally Administered BPM31510 on Mitochondrial Energetics in Older Adults With Sarcopenia

WithdrawnNCT04999488

AdventHealth Translational Research InstituteSarcopenia

Start: 2023-12-31End: 2024-12-31Updated: 2023-07-24

Phase 2

A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)

Active, not recruitingNCT04752813

BPGbioGlioblastoma, Glioblastoma Multiforme

Start: 2022-08-22End: 2030-08-26Target: 50Updated: 2026-01-26

Related Papers

TIP-14. Trial in Progress (TiP): Interim analysis of a Phase 2 study of BPM31510 (a lipid nanodispersion of oxidized CoQ10) with Vitamin K in combination with Standard of Care (SOC) RT and TMZ in Glioblastoma Multiforme (GBM) patients without prior therapy

Neuro-Oncology2025-11-01

TMET-22. BPM31510 engagement of the Warburg effect in GBM to therapeutically modulate tumor metabolism through ROS mediated processes preclinically and clinically

Neuro-Oncology2025-11-01

Abstract CT242: A phase 2 study of BPM31510 (a lipid nanodispersion of oxidized CoQ10) with vitamin K in combination with standard of care (SOC) RT and TMZ in glioblastoma multiforme (GBM) patients without prior therapy

Cancer Research2025-04-25

CTNI-27. <i>TRIAL IN PROGRESS</i> A PHASE 2 STUDY OF BPM 31510 (AN OXIDIZED COQ10-LIPID CONJUGATE NANODISPERSION) WITH VITAMIN K AND STANDARD CHEMORADIATION IN NEWLY DIAGNOSED GLIOBLASTOMA

Neuro-Oncology2023-11-011 citations